Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis: 24-Week Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using Subcutaneous Dosing.

McInnes Iain B.; Mease Philip J.; Kirkham Bruce; Kavanaugh Arthur; Ritchlin Christopher T.; Rahman Proton; van der Heijde Desiree; Landewe Robert B. M.; Conaghan Philip G.; Richards Hanno; Ligozio Gregory; Pricop Luminita; Mpofu Shephard

首页> 外文期刊>Arthritis & rheumatology. >Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis: 24-Week Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using Subcutaneous Dosing.

【24h】

Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis: 24-Week Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using Subcutaneous Dosing.

机译：Secukinumab是一种人类抗白介素17A单克隆抗体，可改善活动型银屑病关节炎：使用皮下给药的一项3期随机，多中心，双盲，安慰剂对照研究的24周疗效和安全性数据。

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Arthritis & rheumatology.》 |2014年第12期|共1页
作者
McInnes Iain B.; Mease Philip J.; Kirkham Bruce; Kavanaugh Arthur; Ritchlin Christopher T.; Rahman Proton; van der Heijde Desiree; Landewe Robert B. M.; Conaghan Philip G.; Richards Hanno; Ligozio Gregory; Pricop Luminita; Mpofu Shephard;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类全身性疾病;
关键词

相似文献

外文文献
中文文献

1. Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis: 24-Week Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using Subcutaneous Dosing. [J] . McInnes Iain B., Mease Philip J., Kirkham Bruce, Arthritis & rheumatology. . 2014,第12期

机译：Secukinumab是一种人类抗白介素17A单克隆抗体，可改善活动型银屑病关节炎：使用皮下给药的一项3期随机，多中心，双盲，安慰剂对照研究的24周疗效和安全性数据。
2. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: A 24-week, randomised, double-blind, placebo-controlled, phase ii proof-of-concept trial [J] . McInnesI.B., SieperJ., BraunJ., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2014,第2期

机译：Secukinumab的疗效和安全性，一种完全人的抗白细胞介素-17A单克隆抗体，中度至严重的银屑病性关节炎患者：24周，随机，双盲，安慰剂控制，第二期概念证明审判
3. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial [J] . McInnes Iain B., Mease Philip J., Kirkham Bruce, The Lancet . 2015,第9999期

机译：Secukinumab是一种人类抗白介素17A单克隆抗体，在银屑病关节炎患者中使用（未来2）：一项随机，双盲，安慰剂对照的3期临床试验
4. Extended report: Ixekizumab an interleukin-17A specific monoclonal antibody for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised double-blind placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1 [O] . Philip J Mease, Désirée van der Heijde, Christopher T Ritchlin, -1

机译：扩展报告：Ixekizumab一种白介素17A特异性单克隆抗体用于治疗初生性活动性银屑病关节炎患者：24周随机双盲安慰剂对照和活性（阿达木单抗）对照期的结果SPIRIT-P1 III期试验
5. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial [O] . McInnes, Iain B., Sieper, Joachim, Braun, Jürgen, 2014

机译：secukinumab，一种完全的人类抗白介素17A单克隆抗体，在中度至重度银屑病关节炎患者中的疗效和安全性：24周，随机，双盲，安慰剂对照，II期概念验证试用

Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis: 24-Week Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using Subcutaneous Dosing.

著录项

相似文献

相关主题

期刊订阅